Wordt geladen...
Single dose oral rofecoxib for acute postoperative pain in adults
BACKGROUND: Editor's note: The anti‐inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long‐term use (greater than 18 months) could increase the risk of heart attack and stroke in a study of secondary prevention of adenoma recu...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Ltd
2009
|
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4171390/ https://ncbi.nlm.nih.gov/pubmed/19821329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004604.pub3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|